Back to Trials
NCT05419518PHASE2Recruiting

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

Rutgers, The State University of New Jersey

Start Date

3/16/2023

Completion Date

4/1/2027

Summary

The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases

Detailed Description

The purpose of this study is to prospectively evaluate dose escalation and pain response in patients with painful non-spinal bone metastases and painful non-bone metastases treated with radiation therapy. Primary Objective: To evaluate improvement of complete pain response rate in painful non-spine bone metastases and painful non-bone metastases with dose escalated radiation using a ten fraction radiation regimen Secondary Objectives: To evaluate best pain response To evaluate mean pain scores To evaluate the duration of pain response To evaluate the changes in quality-of-life following radiation To evaluate the rates of retreatment with radiation secondary to disease or symptom progression To evaluate treatment related toxicity

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Have provided signed informed consent for the trial * Aged ≥18 years at the time of informed consent * Histologic proof of malignancy * Radiologic or histologic evidence of bone metastases or non-bone metastases * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≥3 * Pain Score ≥ 3 * Life expectancy of six months or more * Willing and able to comply with all aspects of the protocol * A female participant is eligible to participate if she is not pregnant and not breastfeeding * Woman of childbearing potential who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. * A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment. Exclusion Criteria: * Metastasis from a highly radiosensitive tumor (eg, lymphoma, myeloma, germ cell tumor) * Spinal metastasis * Active compression of spinal cord/cauda equina * Previous RT or SBRT to the same site * \> 3 sites requiring radiation treatment

Interventions

BIOLOGICAL

EXTERNAL BEAM RADIATION

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Neoplasm MetastasesMetastases, Neoplasm

Locations

RWJBarnabas Health - Robert Wood Johnson University Hospital

Hamilton, New Jersey 08690

United States

RWJBarnabas Health - Monmouth Medical Center Southern Campus

Lakewood, New Jersey 08701

United States

RWJBarnabas Health - Saint Barnabas Medical Center

Livingston, New Jersey 10457

United States

Robert Wood Johnson University Hospital

New Brunswick, New Jersey 08901

United States

Cancer Institute of New Jersey

New Brunswick, New Jersey 08903

United States

RWJBarnabas Health - Robert Wood Johnson University Hospital

Somerset, New Jersey 08876

United States

RWJBarnabas Health - Community Medical Center

Toms River, New Jersey 08755

United States